Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrés Castellanos-Martín is active.

Publication


Featured researches published by Andrés Castellanos-Martín.


Epigenetics | 2013

C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes

Jing Lu; Mingxin Wen; Yurong Huang; Xiuquan He; Yunshan Wang; Qi Wu; Zengchun Li; Andrés Castellanos-Martín; Mar Abad; Juan J. Cruz-Hernández; César A. Rodriguez; Jesus Perez-Losada; Jian-Hua Mao; Guangwei Wei

Recently, it has been suggested that C2ORF40 is a candidate tumor suppressor gene in breast cancer. However, the mechanism for reduced expression of C2ORF40 and its functional role in breast cancers remain unclear. Here we show that C2ORF40 is frequently silenced in human primary breast cancers and cell lines through promoter hypermethylation. C2ORF40 mRNA level is significantly associated with patient disease-free survival and distant cancer metastasis. Overexpression of C2ORF40 inhibits breast cancer cell proliferation, migration and invasion. By contrast, silencing C2ORF40 expression promotes these biological phenotypes. Bioinformatics and FACS analysis reveal C2ORF40 functions at G2/M phase by downregulation of mitotic genes expression, including UBE2C. Our results suggest that C2ORF40 acts as a tumor suppressor gene in breast cancer pathogenesis and progression and is a candidate prognostic marker for this disease.


Genome Biology | 2015

Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach

Andrés Castellanos-Martín; Sonia Castillo-Lluva; María del Mar Sáez-Freire; Adrián Blanco-Gómez; Lourdes Hontecillas-Prieto; Carmen Patino-Alonso; Purificación Galindo-Villardón; Luis Pérez del Villar; Carmen Martín-Seisdedos; María Isidoro-García; María del Mar Abad-Hernández; Juan J. Cruz-Hernández; César Augusto Rodríguez-Sánchez; Rogelio González-Sarmiento; Diego Alonso-López; Javier De Las Rivas; Begoña García-Cenador; Javier García-Criado; Do Yup Lee; Benjamin P. Bowen; Wolfgang Reindl; Trent R. Northen; Jian-Hua Mao; Jesus Perez-Losada

BackgroundAn essential question in cancer is why individuals with the same disease have different clinical outcomes. Progress toward a more personalized medicine in cancer patients requires taking into account the underlying heterogeneity at different molecular levels.ResultsHere, we present a model in which there are complex interactions at different cellular and systemic levels that account for the heterogeneity of susceptibility to and evolution of ERBB2-positive breast cancers. Our model is based on our analyses of a cohort of mice that are characterized by heterogeneous susceptibility to ERBB2-positive breast cancers. Our analysis reveals that there are similarities between ERBB2 tumors in humans and those of backcross mice at clinical, genomic, expression, and signaling levels. We also show that mice that have tumors with intrinsically high levels of active AKT and ERK are more resistant to tumor metastasis. Our findings suggest for the first time that a site-specific phosphorylation at the serine 473 residue of AKT1 modifies the capacity for tumors to disseminate. Finally, we present two predictive models that can explain the heterogeneous behavior of the disease in the mouse population when we consider simultaneously certain genetic markers, liver cell signaling and serum biomarkers that are identified before the onset of the disease.ConclusionsConsidering simultaneously tumor pathophenotypes and several molecular levels, we show the heterogeneous behavior of ERBB2-positive breast cancer in terms of disease progression. This and similar studies should help to better understand disease variability in patient populations.


PLOS ONE | 2012

Multiple novel alternative splicing forms of FBXW7α have a translational modulatory function and show specific alteration in human cancer.

Yueyong Liu; Shancheng Ren; Andrés Castellanos-Martín; Jesus Perez-Losada; Yong-Won Kwon; Yurong Huang; Zeran Wang; Mar Abad; Juan J. Cruz-Hernández; Cesar Rodriguez; Yinghao Sun; Jian-Hua Mao

FBXW7 acts as a tumor suppressor through ubiquitination and degradation of multiple oncoproteins. Loss of FBXW7 expression, which could be partially attributed by the genomic deletion or mutation of FBXW7 locus, is frequently observed in various human cancers. However, the mechanisms regulating FBXW7 expression still remain poorly understood. Here we examined the 5′ region of FBXW7 gene to investigate the regulation of FBXW7 expression. We identified seven alternative splicing (AS) 5′-UTR forms of FBXW7α that are composed of multiple novel non-coding exons. A significant difference in translational efficiency among these 5′-UTRs variants was observed by in vivo Luciferase reporter assay and Western blot. Furthermore, we found that the mRNA level of the AS form with high translational efficiency was specifically reduced in more than 80% of breast cancer cell lines and in more than 50% of human primary cancers from various tissues. In addition, we also identified mutations of FBXW7 in prostate cancers (5.6%), kidney cancers (16.7%), and bladder cancers (18.8%). Our results suggest that in addition to mutation, differential expression of FBXW7α AS forms with different translational properties may serve as a novel mechanism for inactivation of FBXW7 in human cancer.


BioEssays | 2016

Missing heritability of complex diseases: Enlightenment by genetic variants from intermediate phenotypes.

Adrián Blanco-Gómez; Sonia Castillo-Lluva; María del Mar Sáez-Freire; Lourdes Hontecillas-Prieto; Jian-Hua Mao; Andrés Castellanos-Martín; Jesus Perez-Losada

Diseases of complex origin have a component of quantitative genetics that contributes to their susceptibility and phenotypic variability. However, after several studies, a major part of the genetic component of complex phenotypes has still not been found, a situation known as “missing heritability.” Although there have been many hypotheses put forward to explain the reasons for the missing heritability, its definitive causes remain unknown. Complex diseases are caused by multiple intermediate phenotypes involved in their pathogenesis and, very often, each one of these intermediate phenotypes also has a component of quantitative inheritance. Here we propose that at least part of the missing heritability can be explained by the genetic component of intermediate phenotypes that is not detectable at the level of the main complex trait. At the same time, the identification of the genetic component of intermediate phenotypes provides an opportunity to identify part of the missing heritability of complex diseases.


Free Radical Biology and Medicine | 2018

The biological age linked to oxidative stress modifies breast cancer aggressiveness

María del Mar Sáez-Freire; Adrián Blanco-Gómez; Sonia Castillo-Lluva; Aurora Gómez-Vecino; Julie Milena Galvis-Jiménez; Carmen Martín-Seisdedos; María Isidoro-García; Lourdes Hontecillas-Prieto; María Begoña García-Cenador; Francisco Javier García-Criado; Maria C. Patino-Alonso; Purificación Galindo-Villardón; Jian-Hua Mao; Carlos Tejero Prieto; Andrés Castellanos-Martín; Lars Kaderali; Jesus Perez-Losada

ABSTRACT The incidence of breast cancer increases with age until menopause, and breast cancer is more aggressive in younger women. The existence of epidemiological links between breast cancer and aging indicates that both processes share some common mechanisms of development. Oxidative stress is associated with both cancer susceptibility and aging. Here we observed that ERBB2‐positive breast cancer, which developed in genetically heterogeneous ERBB2‐positive transgenic mice generated by a backcross, is more aggressive in chronologically younger than in older mice (differentiated by the median survival of the cohort that was 79 weeks), similar to what occurs in humans. In this cohort, we estimated the oxidative biological age using a mathematical model that integrated several subphenotypes directly or indirectly related to oxidative stress. The model selected the serum levels of HDL‐cholesterol and magnesium and total AKT1 and glutathione concentrations in the liver. The grade of aging was calculated as the difference between the predicted biological age and the chronological age. This comparison permitted the identification of biologically younger and older mice compared with their chronological age. Interestingly, biologically older mice developed more aggressive breast cancer than the biologically younger mice. Genomic regions on chromosomes 2 and 15 linked to the grade of oxidative aging were identified. The levels of expression of Zbp1 located on chromosome 2, a gene related to necroptosis and inflammation, positively correlated with the grade of aging and tumour aggressiveness. Moreover, the pattern of gene expression of genes linked to the inflammation and the response to infection pathways was enriched in the livers of biologically old mice. This study shows part of the complex interactions between breast cancer and aging. HIGHLIGHTSBreast cancer developed by genetically heterogeneous mice was more aggressive in chronologically younger than in older mice.We estimated the biological age integrating subphenotypes related to oxidative stress.Biologically older mice developed more aggressive breast cancer than the biologically younger mice.We identified QTLs genomic regions on chromosomes 2 and 15 linked to the grade of oxidative aging.The pattern of gene expression in the liver of biologically old mice is enriched in inflammation and response to infection pathways.


Oncogene | 2015

A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development

Sonia Castillo-Lluva; Lourdes Hontecillas-Prieto; Adrián Blanco-Gómez; M del Mar Sáez-Freire; Begoña García-Cenador; Javier García-Criado; Martin Perez-Andres; Alberto Orfao; M Cañamero; Jian-Hua Mao; T Gridley; Andrés Castellanos-Martín; Jesus Perez-Losada

Breast cancer is a major cause of mortality in women. The transcription factor SNAI2 has been implicated in the pathogenesis of several types of cancer, including breast cancer of basal origin. Here we show that SNAI2 is also important in the development of breast cancer of luminal origin in MMTV-ErbB2 mice. SNAI2 deficiency leads to longer latency and fewer luminal tumors, both of these being characteristics of pretumoral origin. These effects were associated with reduced proliferation and a decreased ability to generate mammospheres in normal mammary glands. However, the capacity to metastasize was not modified. Under conditions of increased ERBB2 oncogenic activity after pregnancy plus SNAI2 deficiency, both pretumoral defects—latency and tumor load—were compensated. However, the incidence of lung metastases was dramatically reduced. Furthermore, SNAI2 was required for proper postlactational involution of the breast. At 3 days post lactational involution, the mammary glands of Snai2-deficient mice exhibited lower levels of pSTAT3 and higher levels of pAKT1, resulting in decreased apoptosis. Abundant noninvoluted ducts were still present at 30 days post lactation, with a greater number of residual ERBB2+ cells. These results suggest that this defect in involution leads to an increase in the number of susceptible target cells for transformation, to the recovery of the capacity to generate mammospheres and to an increase in the number of tumors. Our work demonstrates the participation of SNAI2 in the pathogenesis of luminal breast cancer, and reveals an unexpected connection between the processes of postlactational involution and breast tumorigenesis in Snai2-null mutant mice.


Data in Brief | 2018

Supplementary data for the biological age linked to oxidative stress modifies breast cancer aggressiveness

María del Mar Sáez-Freire; Adrián Blanco-Gómez; Sonia Castillo-Lluva; Aurora Gómez-Vecino; Julie Milena Galvis-Jiménez; Carmen Martín-Seisdedos; María Isidoro-García; Lourdes Hontecillas-Prieto; María Begoña García-Cenador; Francisco Javier García-Criado; Maria C. Patino-Alonso; Purificación Galindo-Villardón; Jian-Hua Mao; Carlos Tejero Prieto; Andrés Castellanos-Martín; Lars Kaderali; Jesus Perez-Losada

The data presented in this article are related to the research paper entitled “The biological age linked to oxidative stress modifies breast cancer aggressiveness” (M.M. Sáez-Freire, A. Blanco-Gómez, S. Castillo-Lluva, A. Gómez-Vecino, J.M. Galvis-Jiménez, C. Martín-Seisdedos, M. Isidoro-García, L. Hontecillas-Prieto, M.B. García-Cenador, F.J. García-Criado, M.C. Patino-Alonso, P. Galindo-Villardón, J.H. Mao, C. Prieto, A. Castellanos-Martín, L. Kaderali, J. Pérez-Losada). The data shown were obtained from a population of transgenic mice, MMTV-Erbb2/Neu, with different susceptibility to breast cancer and a mixed genetic background generated by backcrossing. It was observed that the aggressiveness of breast cancer negatively correlates with age, being lower in chronologically old mice, similar to what occurs in humans. Given that oxidative stress is associated with tumour susceptibility and the degree of aging, the association between the aggressiveness of breast cancer and multiple intermediate phenotypes directly or indirectly related to oxidative stress was studied. Using a mathematical model, we defined biological age and the degree of aging as the difference between biological and chronological ages. As a result, we observed that biologically old mice predominated among those that developed the disease early on, that is, those that were chronologically young. We then identified the specific and common genetic components of Quantitative Trait loci or QTL associated with different evolution of breast cancer, the intermediate phenotypes related to oxidative stress studied, the biological age and the degree of aging. Lastly, we showed that the expression pattern in the livers of biologically old mice were enriched in signalling pathways related to inflammation and response to infections; whereas the biologically young mice exhibited enriched pathways related to mitochondrial activity. For the explanation and discussion of these data refer to the research article cited above.


British Journal of Dermatology | 2017

MicroRNA (miR)-203 and miR-205 expression patterns identify subgroups of prognosis in cutaneous squamous cell carcinoma

J. Cañueto; E. Cardeñoso-Álvarez; J.L. García-Hernández; Purificación Galindo-Villardón; P. Vicente-Galindo; J.L. Vicente-Villardón; D. Alonso-López; J. de las Rivas; J. Valero; E. Moyano-Sanz; E. Fernández-López; Jian-Hua Mao; Andrés Castellanos-Martín; C. Román-Curto; Jesus Perez-Losada

Cutaneous squamous cell carcinoma (CSCC) is the second most widespread cancer in humans and its incidence is rising. These tumours can evolve as diseases of poor prognosis, and therefore it is important to identify new markers to better predict its clinical evolution.


Integrative Biology | 2011

Cancer evolution and individual susceptibility

Jesus Perez-Losada; Andrés Castellanos-Martín; Jian-Hua Mao


Archive | 2016

Breast cancer phenotypic variability is affected by the biological age

María del Mar Sáez-Freire; Adrián Blanco-Gómez; Sonia Castillo; Chris Lauber; Maria C. Patino-Alonso; Purificación Galindo-Villardón; Carmen Martín-Seisdedos; María Isidoro-García; María E. Muñoz; Julie Milena Galvis-Jiménez; Trent R. Northen; Andrés Castellanos-Martín; Lars Kaderali; Jesus Perez-Losada

Collaboration


Dive into the Andrés Castellanos-Martín's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jian-Hua Mao

Lawrence Berkeley National Laboratory

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge